Skip to main content
Caplight Logo









Xylo Bio

Xylo Bio

Private
Boulder, ColoradoHealthcare & Life Scienceshttps://xylo.bio/

Last Round

Grant

Oct 28, 2024

Total Funding Raised

$9.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Xylo Bio is a biotechnology company that develops targeted neuroplastogen therapies designed to rewire neural circuits and restore brain function for patients with psychiatric and neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

neuroplastogenscomputational drug discoveryai drug discoverysmall molecule therapeuticsneurotherapeuticspsychedelic medicinenon-hallucinogenicdrug developmentmental health techvirtual screeningstructure-based designbiotechmolecular dockingpharma r&d

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xylo Bio Comparables

Compare Xylo Bio with similar companies based on industry and business-model similarity.

Xylo Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delix Therapeutics
89%
Gilgamesh Pharmaceuticals
88%
Kasvu Therapeutics
86%

Xylo Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 28, 2024
SeedJun 3, 2024
SeedOct 1, 2022
AcceleratorOct 1, 2021

Key People

Founding team and executive leadership

Sam Banister

Co-founder and Chief Scientific Officer

Founding Team

Xylo Bio Investors

Notable investors and investment history

Xylo Bio investors
InvestorRounds
StartmateAccelerator
Main Sequence VenturesSeed
GaingelsSeed
Lionheart VenturesSeed
Negev CapitalSeed
Mystic VenturesSeed
Palo SantoSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 32% MoM.

  • Apr 16, 2026

    Monthly visitors increased 135% MoM, reaching 8.6K.

Xylo Bio Filings

Explore SEC and related filing metadata, where available.

Xylo Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Xylo Bio's valuation, stock price, and market status.

Is Xylo Bio a public or private company?

Xylo Bio is a private company.

What is the current stock price of Xylo Bio?

Xylo Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Xylo Bio worth (valuation)?

Valuation information for Xylo Bio is not publicly available.

Can I buy Xylo Bio stock?

Xylo Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Xylo Bio's last funding round?

Xylo Bio's most recent funding round was Grant on October 28, 2024.

Who are the main investors in Xylo Bio?

Key investors in Xylo Bio include Main Sequence Ventures, Possible Ventures, Tenmile.

Will Xylo Bio IPO soon?

No public IPO plans have been announced for Xylo Bio.

How can I track Xylo Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Xylo Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoulder, Colorado
Employee Range21
Year Founded2021
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?